Bausch Health Companies Inc. agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800 percent price hike in 2015.

HIV-prevention advocacy group PrEP4All Collaboration filed a petition with the U.S. Patent and Trademark Office alleging that Gilead Sciences intentionally delayed the development of a safer drug for human immunodeficiency virus.